RecruitingNot ApplicableNCT06689241
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial
Sponsor
Alexandria University
Enrollment
162 participants
Start Date
Oct 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
Eligibility
Min Age: 20 YearsMax Age: 60 Years
Inclusion Criteria3
- Age: 20-60 years, both sexes.
- ASA physical status class I to III.
- BMI 35-50 kg/m²
Exclusion Criteria4
- Severe cardiac disorder
- chronic renal failure
- liver cirrhosis
- major psychological disorder
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEnoxaparin
40mg
DRUGrivaroxaban
10mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06689241
Related Trials
Determinants of the Long-Term Success of Bariatric Surgery
NCT035170724 locations
Effect of Transcutaneous Electrical Nerve Stimulation on PODD in Bariatric Surgery Patients
NCT075697052 locations
Stool Analysis After Sleeve Gastrectomy vs Gastric Bypass
NCT074616101 location
Metabolic Responses to Bariatric Surgery
NCT020245421 location
Gut Microbiome and Sex as Risk Factors for Kidney Stones After Bariatric Surgery
NCT045906901 location